Galvus(R) Better Tolerated By Type 2 Diabetes Patients With No Weight Gain, A Favorable Cardiovascular Profile And Equal Efficacy Compared To TZDs
Galvus(R) Better Tolerated By Type 2 Diabetes Patients With No Weight Gain, A Favorable Cardiovascular Profile And Equal Efficacy Compared To TZDs
10 Sep 2008
MedicalNewsToday.com
New data show Galvus® (vildagliptin), an oral treatment for type 2 diabetes, is better tolerated and as effective as commonly prescribed anti-diabetic oral medicines, called thiazolidinediones (TZDs), when added to metformin1. Patients treated with Galvus did not gain weight, a common side effect of other type 2 diabetes medicines, regardless of their race, body mass index or age1.
The results come from GALIANT, a study involving more than 2,400 patients treated by primary care physicians1. The GALIANT data were presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Rome, Italy.
Type 2 diabetes is estimated to affect more than 53 million people in Europe4. Controlling blood sugar is difficult and up to 65% of diabetes patients fail to meet their recommended blood sugar levels5. When left untreated or not kept under control, type 2 diabetes can lead to heart and kidney disease, blindness and vascular or neurological problems6.
Other data presented at EASD demonstrated the favorable cardiovascular safety profile of Galvus2 and confirmed its tolerability in patients with mild-to-moderate renal impairment3.
Please visit the website to view the entire article.
2009 MediLexicon International Ltd
